• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 4. Estimation of hydrogen sulfide from crude petroleum: a unique invention using a simple chemosensor?
  Shampa Kundu,Prithidipa Sahoo New J. Chem., 2019,43, 12369-12374
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

Introduction to 3-ethyl-1-(3-methylphenyl)pentan-1-amine (CAS No: 1548307-09-0)

3-ethyl-1-(3-methylphenyl)pentan-1-amine, identified by the Chemical Abstracts Service Number (CAS No) 1548307-09-0, is a specialized organic compound that has garnered attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the class of amine derivatives, characterized by its complex aliphatic and aromatic structural motifs. The presence of both ethyl and methyl substituents, along with a phenyl ring at the 3-position, contributes to its unique chemical properties and potential biological activities.

The molecular structure of 3-ethyl-1-(3-methylphenyl)pentan-1-amine consists of a pentanamine backbone with an ethyl group at the 3-position and a 3-methylphenyl group attached to the first carbon. This arrangement creates a molecule with distinct steric and electronic characteristics, which are crucial for its interaction with biological targets. The compound’s solubility, stability, and metabolic pathways are influenced by these structural features, making it a subject of interest for drug design and development.

In recent years, there has been a growing interest in amine-based compounds due to their versatile pharmacological properties. Amines are known to play a pivotal role in the synthesis of various bioactive molecules, including neurotransmitters, hormones, and pharmaceutical agents. The specific configuration of 3-ethyl-1-(3-methylphenyl)pentan-1-amine suggests potential applications in modulating neurological and cardiovascular functions, although extensive research is still required to fully elucidate its therapeutic profile.

One of the most compelling aspects of 3-ethyl-1-(3-methylphenyl)pentan-1-amine is its structural similarity to known pharmacophores that exhibit significant biological activity. For instance, compounds with similar aromatic and aliphatic moieties have been investigated for their roles in pain relief, anxiety modulation, and even as intermediates in the synthesis of more complex drugs. The incorporation of both ethyl and methyl groups enhances the compound’s lipophilicity, which is often a desirable trait for oral bioavailability and membrane permeability.

The synthesis of 3-ethyl-1-(3-methylphenyl)pentan-1-amine involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. Advanced synthetic methodologies, such as cross-coupling reactions and catalytic hydrogenation, are commonly employed to construct the desired molecular framework. The efficiency and yield of these synthetic routes are critical factors that determine the feasibility of large-scale production for research or commercial purposes.

Recent advancements in computational chemistry have enabled researchers to predict the biological activity of compounds like 3-ethyl-1-(3-methylphenyl)pentan-1-amine with greater accuracy before conducting costly wet-lab experiments. Molecular docking studies have shown that this compound may interact with various protein targets, including enzymes and receptors involved in metabolic pathways. Such insights are invaluable for identifying potential therapeutic applications and optimizing drug-like properties.

The pharmacokinetic behavior of 3-ethyl-1-(3-methylphenyl)pentan-1-amine is another area of active investigation. Understanding how the body processes this compound—its absorption, distribution, metabolism, and excretion (ADME)—is essential for developing safe and effective pharmaceutical formulations. Preclinical studies using animal models have begun to shed light on these processes, providing preliminary data on its bioavailability and potential side effects.

In conclusion, 3-ethyl-1-(3-methylphenyl)pentan-1-amine (CAS No: 1548307-09) represents a promising candidate for further exploration in medicinal chemistry. Its unique structural features offer potential advantages in drug design, particularly in modulating neurological and cardiovascular functions. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in the development of novel therapeutic agents.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)